Apolipoprotein B and non-high-density lipoprotein cholesterol reveal a high atherogenicity in individuals with type 2 diabetes and controlled low-density lipoprotein-cholesterol

Table 2 Comparison of lipid profile between type 2 diabetes patients with LDL-c within and above target (2016 guidelines criteria)

	n	LDL-c within target	n	LDL-c above target	p
LDL-c (mg/dL)	27	65 (53–70)	69	109.0 (92.5–133.0)	< 0.001
Total cholesterol (mg/dL)	27	146 (125–162)	69	180.0 (74.3–107.8)	< 0.001
ApoB (mg/dL)	24	67.0 (58.8–79.0)	64	85.0 (74.3–107.8)	< 0.001
ApoA1 (F) (mg/dL)	8	167.5 (123.0–193.5)	27	155 (140–180)	0.556
ApoA1 (M) (mg/dL)	15	130 (102–143)	33	134.0 (116.5–139.5)	0.772
ApoB/ApoA1 ratio	22	0.54 (0.41–0.64)	60	0.63 (0.54–0.76)	0.004
Non-HDL-c* (mg/dL)	27	99.0 (85.0–118.0)	69	142.2 (119.5–166.5)	< 0.001
Oxidized LDL-c* (U/L)	27	115.7 (94.5–162.1)	69	150.8 (117.3–193.4)	0.007
*Lipoprotein (a) (mg/dL)**	22	9.5 (4.0–34.5)	62	25 (5.75–58.10)	0.106

Data are presented as mean ± standard deviation, unless otherwise indicated by ∗ corresponding to data presented as median, 25th and 75th percentiles. LDL-c Low-density lipoprotein cholesterol, ApoB Apolipoprotein B, ApoA1 Apolipoprotein A1, M male, F female, Non-HDL-c non-nigh-density lipoprotein cholesterol

ISSN: 1476-511X